Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Neoplasms of the CNS

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 223 articles:
HTML format



Single Articles


    June 2021
  1. ANWAR M, Chen Q, Ouyang D, Wang S, et al
    Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0474.
    PubMed     Abstract available


  2. DI GIACOMO AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, et al
    Primary analysis and four-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-1046.
    PubMed     Abstract available


  3. WU AML, Gossa S, Samala R, Chung MA, et al
    Aging and CNS myeloid cell depletion attenuate breast cancer brain metastasis.
    Clin Cancer Res. 2021 Jun 3. pii: 1078-0432.CCR-21-1549.
    PubMed     Abstract available


  4. MELLINGHOFF IK, Penas-Prado M, Peters KB, Burris HA, et al
    Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; Results of a first-in-human Phase I trial.
    Clin Cancer Res. 2021 Jun 2. pii: 1078-0432.CCR-21-0611.
    PubMed     Abstract available


    May 2021
  5. SABBAGH A, Beccaria K, Ling X, Marisetty A, et al
    Opening of the blood-brain barrier using low-intensity pulsed ultrasound enhances responses to immunotherapy in preclinical glioma models.
    Clin Cancer Res. 2021 May 24. pii: 1078-0432.CCR-20-3760.
    PubMed     Abstract available


  6. KITAGAWA Y, Tanaka S, Kamiya M, Kuriki Y, et al
    A Novel Topical Fluorescent Probe for Detection of Glioblastoma.
    Clin Cancer Res. 2021 May 23. pii: 1078-0432.CCR-20-4518.
    PubMed     Abstract available


  7. WERNER JM, Weller J, Ceccon G, Schaub C, et al
    Diagnosis of pseudoprogression following lomustine-temozolomide chemoradiation in newly diagnosed glioblastoma patients using FET PET.
    Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-21-0471.
    PubMed     Abstract available


    April 2021
  8. ELLINGSON BM, Sampson JH, Achrol AS, Aghi MK, et al
    Modified RANO (mRANO), iRANO, and standard RANO response to convection-enhanced delivery of IL4R-targeted immunotoxin MDNA55 in recurrent glioblastoma.
    Clin Cancer Res. 2021 Apr 16. pii: 1078-0432.CCR-21-0446.
    PubMed     Abstract available


    March 2021
  9. TOLANEY SM, Sahebjam S, Rhun EL, Bachelot T, et al
    Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer.
    Clin Cancer Res. 2021;27:1582.
    PubMed    


    February 2021
  10. DEWIRE MD, Fuller C, Campagne O, Lin T, et al
    A Phase I and surgical study of ribociclib and everolimus in children with recurrent or refractory malignant brain tumors: a Pediatric Brain Tumor Consortium Study.
    Clin Cancer Res. 2021 Feb 5. pii: 1078-0432.CCR-20-4078.
    PubMed     Abstract available


  11. OTVOS B, Alban TJ, Grabowski MM, Bayik D, et al
    Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome.
    Clin Cancer Res. 2021 Feb 4. pii: 1078-0432.CCR-20-3262.
    PubMed     Abstract available


  12. BASHIR A, Larsen VA, Ziebell M, Fugleholm K, et al
    Improved detection of postoperative residual meningioma with [68Ga]Ga-DOTA-TOC PET imaging using a high-resolution research tomograph (HRRT) PET scanner.
    Clin Cancer Res. 2021 Feb 1. pii: 1078-0432.CCR-20-3362.
    PubMed     Abstract available


    January 2021
  13. ANDREWS DW, Judy K, Scott CB, Garcia S, et al
    Phase 1b Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma.
    Clin Cancer Res. 2021 Jan 26. pii: 1078-0432.CCR-20-3805.
    PubMed     Abstract available


  14. NAGLE VL, Henry KE, Hertz CAJ, Graham MS, et al
    Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [(64)Cu]Cu-NOTA-anti-CD8-Positron Emission Tomography.
    Clin Cancer Res. 2021 Jan 25. pii: 1078-0432.CCR-20-3243.
    PubMed     Abstract available


    December 2020
  15. SEIDLITZ A, Beuthien-Baumann B, Lock S, Jentsch C, et al
    Final results of the prospective biomarker trial PETra: [(11)C]-MET-accumulation in postoperative PET/MRI predicts outcome after radiochemotherapy in glioblastoma.
    Clin Cancer Res. 2020 Dec 29. pii: 1078-0432.CCR-20-1775.
    PubMed     Abstract available


  16. STADLBAUER A, Kinfe TM, Eyupoglu I, Zimmermann M, et al
    Tissue hypoxia and alterations in microvascular architecture predict glioblastoma recurrence in humans.
    Clin Cancer Res. 2020 Dec 8. pii: 1078-0432.CCR-20-3580.
    PubMed     Abstract available


  17. CHASTKOFSKY MI, Pituch KC, Katagi H, Zannikou M, et al
    Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.
    Clin Cancer Res. 2020 Dec 3. pii: 1078-0432.CCR-20-1499.
    PubMed     Abstract available


    November 2020
  18. KIYOKAWA J, Kawamura Y, Ghouse SM, Acar S, et al
    Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma.
    Clin Cancer Res. 2020 Nov 30. pii: 1078-0432.CCR-20-2400.
    PubMed     Abstract available


  19. IORGULESCU JB, Gokhale PC, Speranza MC, Eschle BK, et al
    Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
    Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-2291.
    PubMed     Abstract available


  20. NAYAK L, Molinaro AM, Peters KB, Clarke JL, et al
    Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for recurrent glioblastoma patients.
    Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-2500.
    PubMed     Abstract available


  21. VIGNESWARAN K, Boyd NH, Oh SY, Lallani S, et al
    YAP/TAZ transcriptional co-activators create therapeutic vulnerability to verteporfin in EGFR mutant glioblastoma.
    Clin Cancer Res. 2020 Nov 10. pii: 1078-0432.CCR-20-0018.
    PubMed     Abstract available


    October 2020
  22. ESTEVE-CODINA A, Alameda F, Carrato C, Pineda E, et al
    RNA-Sequencing and immunohistochemistry reveal ZFN7 as a stronger marker of survival than molecular subtypes in G-CIMP-negative glioblastoma.
    Clin Cancer Res. 2020 Oct 26. pii: 1078-0432.CCR-20-2141.
    PubMed     Abstract available


  23. BRUZEK AK, Ravi K, Muruganand A, Wadden J, et al
    Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma.
    Clin Cancer Res. 2020 Oct 21. pii: 1078-0432.CCR-20-2066.
    PubMed     Abstract available


  24. MONTAY-GRUEL P, Acharya MM, Goncalves Jorge P, Petit B, et al
    Hypo-fractionated FLASH-RT as an effective treatment against glioblastoma that reduces neurocognitive side effects in mice.
    Clin Cancer Res. 2020 Oct 15. pii: 1078-0432.CCR-20-0894.
    PubMed     Abstract available


  25. MURALIDHARAN K, Yekula A, Small JL, Rosh ZS, et al
    TERT promoter mutation analysis for blood-based diagnosis and monitoring of gliomas.
    Clin Cancer Res. 2020 Oct 13. pii: 1078-0432.CCR-20-3083.
    PubMed     Abstract available


  26. PARK JE, Kim HS, Kim N, Park SY, et al
    Spatiotemporal Heterogeneity in Multiparametric Physiologic MRI Are Associated with Patient Outcomes in IDH-wildtype Glioblastoma.
    Clin Cancer Res. 2020 Oct 7. pii: 1078-0432.CCR-20-2156.
    PubMed     Abstract available


    September 2020
  27. CARRATO C, Alameda F, Esteve-Codina A, Pineda E, et al
    Glioblastoma TCGA mesenchymal and IGS 23 tumors are identifiable by immunohistochemistry and have an immune-phenotype indicating potential benefit from immunotherapy.
    Clin Cancer Res. 2020 Sep 30. pii: 1078-0432.CCR-20-2171.
    PubMed     Abstract available


  28. WIRSCHING HG, Roelcke U, Weller J, Hundsberger T, et al
    MRI and 18FET-PET predict survival benefit from bevacizumab plus radiotherapy in patients with IDH wild-type glioblastoma: results from the randomized ARTE trial.
    Clin Cancer Res. 2020 Sep 23. pii: 1078-0432.CCR-20-2096.
    PubMed     Abstract available


  29. FERREIRA S, Foray C, Gatto A, Larcher M, et al
    AsiDNA is a radiosensitizer with no added toxicity in medulloblastoma pediatric models.
    Clin Cancer Res. 2020 Sep 8. pii: 1078-0432.CCR-20-1729.
    PubMed     Abstract available


    August 2020
  30. ACCOMANDO WP, Rao AR, Hogan DJ, Newman AM, et al
    Molecular and immunological signatures are related to clinical benefit from treatment with Vocimagene amiretrorepvec (Toca 511) and 5-fluorocytosine (Toca FC) in patients with glioma.
    Clin Cancer Res. 2020 Aug 18. pii: 1078-0432.CCR-20-0536.
    PubMed     Abstract available


  31. WILDES TJ, Dyson KA, Francis CP, Wummer BM, et al
    Immune escape after adoptive T cell therapy for malignant gliomas.
    Clin Cancer Res. 2020 Aug 11. pii: 1078-0432.CCR-20-1065.
    PubMed     Abstract available


    July 2020
  32. BATICH KA, Mitchell DA, Healy P, Herndon JE, et al
    Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.
    Clin Cancer Res. 2020 Jul 27. pii: 1078-0432.CCR-20-1082.
    PubMed     Abstract available


  33. TOLANEY SM, Sahebjam S, Le Rhun E, Bachelot T, et al
    A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1764.
    PubMed     Abstract available


  34. YE Z, Price RL, Liu X, Lin J, et al
    Diffusion Histology Imaging Combining Diffusion Basis Spectrum Imaging (DBSI) and Machine Learning Improves Detection and Classification of Glioblastoma Pathology.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-0736.
    PubMed     Abstract available


  35. GOERIG NL, Frey B, Korn K, Fleckenstein B, et al
    Early Mortality of Brain Cancer Patients and its Connection to Cytomegalovirus Reactivation During Radiochemotherapy.
    Clin Cancer Res. 2020;26:3259-3270.
    PubMed     Abstract available


    June 2020
  36. OTT M, Kassab C, Marisetty A, Hashimoto Y, et al
    Radiation with STAT3 blockade triggers dendritic cell-T cell interactions in the glioma microenvironment and therapeutic efficacy.
    Clin Cancer Res. 2020 Jun 30. pii: 1078-0432.CCR-19-4092.
    PubMed     Abstract available


  37. RAO G, Latha K, Ott M, Sabbagh A, et al
    Anti-PD-1 induces M1 polarization in the glioma microenvironment and exerts therapeutic efficacy in the absence of CD8 cytotoxic T cells.
    Clin Cancer Res. 2020 Jun 18. pii: 1078-0432.CCR-19-4110.
    PubMed     Abstract available


  38. LADOMERSKY E, Zhai L, Lauing KL, Bell A, et al
    Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.
    Clin Cancer Res. 2020 Jun 16. pii: 1078-0432.CCR-19-3874.
    PubMed     Abstract available


  39. KHASRAW M, Reardon DA, Weller M, Sampson JH, et al
    PD-1 inhibitors: Do they have a future in the treatment of glioblastoma?
    Clin Cancer Res. 2020 Jun 11. pii: 1078-0432.CCR-20-1135.
    PubMed     Abstract available


  40. INDRACCOLO S, De Salvo GL, Verza M, Caccese M, et al
    Phosphorylated Acetyl-CoA Carboxylase is associated with clinical benefit with Regorafenib in relapsed glioblastoma: REGOMA Trial Biomarker Analysis.
    Clin Cancer Res. 2020 Jun 9. pii: 1078-0432.CCR-19-4055.
    PubMed     Abstract available


    May 2020
  41. SCHEETZ L, Kadiyala P, Sun X, Son S, et al
    Synthetic high-density lipoprotein nanodiscs for personalized immunotherapy against gliomas.
    Clin Cancer Res. 2020 May 21. pii: 1078-0432.CCR-20-0341.
    PubMed     Abstract available


  42. KANE JR, Zhao J, Tsujiuchi T, Laffleur B, et al
    CD8(+) T-cell-mediated immunoediting influences genomic evolution and immune evasion in murine gliomas.
    Clin Cancer Res. 2020 May 19. pii: 1078-0432.CCR-19-3104.
    PubMed     Abstract available


  43. STRAGLIOTTO G, Pantalone MR, Rahbar A, Bartek J, et al
    Valganciclovir as add-on to standard therapy in glioblastoma patients.
    Clin Cancer Res. 2020 May 18. pii: 1078-0432.CCR-20-0369.
    PubMed     Abstract available


  44. BAGLEY SJ, Carpenter EL
    Plasma cfDNA in Glioblastoma-Response.
    Clin Cancer Res. 2020;26:2276.
    PubMed    


  45. TAKAYASU T, Esquenazi Y, Ballester LY
    Plasma cfDNA in Glioblastoma-Letter.
    Clin Cancer Res. 2020;26:2275.
    PubMed    


    April 2020
  46. EGUREN-SANTAMARIA I, Sanmamed MF, Goldberg SB, Kluger HM, et al
    PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice.
    Clin Cancer Res. 2020 Apr 30. pii: 1078-0432.CCR-20-0798.
    PubMed     Abstract available


  47. MENDEZ F, Kadiyala P, Nunez FJ, Carney S, et al
    Therapeutic efficacy of immune stimulatory thymidine kinase and fms-like tyrosine kinase 3 ligand (TK/Flt3L) gene therapy in a mouse model of high grade brainstem glioma.
    Clin Cancer Res. 2020 Apr 24. pii: 1078-0432.CCR-19-3714.
    PubMed     Abstract available


  48. LEE JH, Menzies AM, Carlino MS, McEvoy AC, et al
    Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors.
    Clin Cancer Res. 2020 Apr 22. pii: 1078-0432.CCR-19-3926.
    PubMed     Abstract available


  49. WEATHERS SP, Penas-Prado M, Pei BL, Ling X, et al
    Glioblastoma-mediated immune dysfunction limits CMV-specific T cells and therapeutic responses; results from a Phase I/II trial.
    Clin Cancer Res. 2020 Apr 16. pii: 1078-0432.CCR-20-0176.
    PubMed     Abstract available


  50. LAWLER SE, Chiocca EA, Cook CH
    Cytomegalovirus encephalopathy during brain tumor irradiation.
    Clin Cancer Res. 2020 Apr 10. pii: 1078-0432.CCR-20-0646.
    PubMed     Abstract available


  51. ELLINGSON BM, Yao J, Raymond C, Nathanson DA, et al
    Multi-parametric MR-PET imaging predicts pharmacokinetics and clinical response to GDC-0084 in patients with recurrent high-grade glioma.
    Clin Cancer Res. 2020 Apr 8. pii: 1078-0432.CCR-19-3817.
    PubMed     Abstract available


    March 2020
  52. COLE KA, Pal S, Kudgus RA, Ijaz H, et al
    Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
    Clin Cancer Res. 2020;26:1213-1219.
    PubMed     Abstract available


  53. MEEL MH, de Gooijer MC, Metselaar DS, Sewing ACP, et al
    Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma.
    Clin Cancer Res. 2020 Mar 12. pii: 1078-0432.CCR-19-3538.
    PubMed     Abstract available


  54. OTANI Y, Yoo JY, Chao S, Liu J, et al
    Oncolytic HSV infected glioma cells activate NOTCH in adjacent tumor cells sensitizing tumors to gamma secretase inhibition.
    Clin Cancer Res. 2020 Mar 5. pii: 1078-0432.CCR-19-3420.
    PubMed     Abstract available


  55. KINSLOW CJ, Canoll P, Cheng SK, Wang TJC, et al
    Misclassification of Diffuse Gliomas-Letter.
    Clin Cancer Res. 2020;26:1198.
    PubMed    


  56. KEMENY HR, Elsamadicy AA, Farber SH, Champion CD, et al
    Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.
    Clin Cancer Res. 2020;26:1141-1151.
    PubMed     Abstract available


    February 2020
  57. BEIG N, Bera K, Prasanna P, Antunes J, et al
    Radiogenomic-Based Survival Risk Stratification of Tumor Habitat on Gd-T1w MRI Is Associated with Biological Processes in Glioblastoma.
    Clin Cancer Res. 2020 Feb 20. pii: 1078-0432.CCR-19-2556.
    PubMed     Abstract available


  58. PIROVANO G, Jannetti SA, Carter LM, Sadique A, et al
    Targeted brain tumor radiotherapy using an Auger emitter.
    Clin Cancer Res. 2020 Feb 17. pii: 1078-0432.CCR-19-2440.
    PubMed     Abstract available


  59. VAZQUEZ-BORREGO MC, Gupta V, Ibanez-Costa A, Gahete MD, et al
    A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors.
    Clin Cancer Res. 2020;26:957-969.
    PubMed     Abstract available


  60. DIRKS PB, Gilbert MR, Holland EC, Maher EA, et al
    Translating basic science discoveries into improved outcomes for glioblastoma.
    Clin Cancer Res. 2020 Feb 14. pii: 1078-0432.CCR-19-3924.
    PubMed     Abstract available


  61. WICK W, Wagener RJ
    Not yet another negative trial - ReACTing on recent glioblastoma trials!
    Clin Cancer Res. 2020 Feb 7. pii: 1078-0432.CCR-19-4032.
    PubMed     Abstract available


  62. REARDON DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, et al
    Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
    Clin Cancer Res. 2020 Feb 7. pii: 1078-0432.CCR-18-1140.
    PubMed     Abstract available


  63. ZHANG IY, Zhou H, Liu H, Zhang L, et al
    Local and Systemic Immune Dysregulation Alters Glioma Growth in Hyperglycemic Mice.
    Clin Cancer Res. 2020 Feb 4. pii: 1078-0432.CCR-19-2520.
    PubMed     Abstract available


  64. TANG B, Guo ZS, Bartlett DL, Yan DZ, et al
    Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
    Clin Cancer Res. 2020 Feb 4. pii: 1078-0432.CCR-18-3626.
    PubMed     Abstract available


  65. PASSARO C, Alayo Q, DeLaura I, McNulty J, et al
    Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.
    Clin Cancer Res. 2020;26:758.
    PubMed    


    January 2020
  66. MOHME M, Maire CL, Geumann U, Schliffke S, et al
    Local intracerebral immunomodulation using interleukin-expressing mesenchymal stem cells in glioblastoma.
    Clin Cancer Res. 2020 Jan 27. pii: 1078-0432.CCR-19-0803.
    PubMed     Abstract available


  67. KUMTHEKAR P, Tang SC, Brenner AJ, Kesari S, et al
    ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-3258.
    PubMed     Abstract available


  68. GRAILLON T, Sanson M, Campello C, Idbaih A, et al
    Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-2109.
    PubMed     Abstract available


  69. NASSIRI F, Taslimi S, Wang JZ, Badhiwala JH, et al
    Determining the optimal adjuvant therapy for improving survival in elderly patients with glioblastoma: a systematic review and meta-analysis.
    Clin Cancer Res. 2020 Jan 17. pii: 1078-0432.CCR-19-3359.
    PubMed     Abstract available


  70. POCHA K, Mock A, Rapp C, Dettling S, et al
    Surfactant expression defines an inflamed subtype of lung adenocarcinoma brain metastases that correlates with prolonged survival.
    Clin Cancer Res. 2020 Jan 17. pii: 1078-0432.CCR-19-2184.
    PubMed     Abstract available


  71. WEN PY, Cloughesy TF, Olivero AG, Morrissey KM, et al
    First-in-human Phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.
    Clin Cancer Res. 2020 Jan 14. pii: 1078-0432.CCR-19-2808.
    PubMed     Abstract available


  72. RODRIGUEZ GUTIERREZ D, Jones C, Varlet P, Mackay A, et al
    Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial.
    Clin Cancer Res. 2020 Jan 10. pii: 1078-0432.CCR-19-3154.
    PubMed     Abstract available


  73. TU Y, Chen Z, Zhao P, Sun G, et al
    Smoothened promotes glioblastoma radiation resistance via activating USP3-mediated Claspin deubiquitination.
    Clin Cancer Res. 2020 Jan 3. pii: 1078-0432.CCR-19-1515.
    PubMed     Abstract available


  74. HIGUCHI F, Nagashima H, Ning J, Koerner MVA, et al
    Restoration of Temozolomide Sensitivity by Poly(ADP-Ribose) Polymerase inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
    Clin Cancer Res. 2020 Jan 3. pii: 1078-0432.CCR-19-2000.
    PubMed     Abstract available


    December 2019
  75. WORONIECKA KI, Rhodin KE, Dechant CA, Waibl Polania J, et al
    4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
    Clin Cancer Res. 2019 Dec 23. pii: 1078-0432.CCR-19-1068.
    PubMed     Abstract available


  76. WU S, Gao F, Zheng S, Zhang C, et al
    EGFR amplification induces increased DNA damage response and renders selective sensitivity to Talazoparib (PARP inhibitor) in glioblastoma.
    Clin Cancer Res. 2019 Dec 18. pii: 1078-0432.CCR-19-2549.
    PubMed     Abstract available


  77. VAUBEL RA, Tian S, Remonde D, Schroeder MA, et al
    Genomic and phenotypic characterization of a broad panel of patient derived xenografts reflects the diversity of glioblastoma.
    Clin Cancer Res. 2019 Dec 18. pii: 1078-0432.CCR-19-0909.
    PubMed     Abstract available


  78. ZHANG DY, Dmello C, Chen L, Arrieta VA, et al
    Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations.
    Clin Cancer Res. 2019 Dec 12. pii: 1078-0432.CCR-19-2182.
    PubMed     Abstract available


  79. HARGRAVE DR, Bouffet E, Tabori U, Broniscer A, et al
    Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study.
    Clin Cancer Res. 2019 Dec 6. pii: 1078-0432.CCR-19-2177.
    PubMed     Abstract available


  80. CAMPAGNE O, Zhong B, Nair S, Lin T, et al
    Exposure-Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing.
    Clin Cancer Res. 2019 Dec 3. pii: 1078-0432.CCR-19-2685.
    PubMed     Abstract available


    October 2019
  81. BAGLEY S, Nabavizadeh SA, Mays J, Till JE, et al
    Clinical utility of plasma cell-free DNA in adult patients with newly diagnosed glioblastoma - a pilot prospective study.
    Clin Cancer Res. 2019 Oct 30. pii: 1078-0432.CCR-19-2533.
    PubMed     Abstract available


  82. PARADA CA, Osbun JW, Busald T, Karasozen Y, et al
    Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals Rb1 signaling as a Novel Mediator and Biomarker.
    Clin Cancer Res. 2019 Oct 15. pii: 1078-0432.CCR-18-0641.
    PubMed     Abstract available


    September 2019
  83. GERSTNER E, Emblem KE, Chang K, Vakulenko-Lagun B, et al
    Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-19-1739.
    PubMed     Abstract available


  84. VAN DER VOORT SR, Incekara F, Wijnenga MM, Kapsas G, et al
    Predicting the 1p/19q co-deletion status of presumed low grade glioma with an externally validated machine learning algorithm.
    Clin Cancer Res. 2019 Sep 23. pii: 1078-0432.CCR-19-1127.
    PubMed     Abstract available


  85. SHARIFI Z, Abdulkarim B, Meehan B, Rak J, et al
    Antitumor Activity of a Binary EGFR/DNA Targeting Strategy Overcomes Resistance of Glioblastoma Stem cells to Temozolomide.
    Clin Cancer Res. 2019 Sep 20. pii: 1078-0432.CCR-19-0955.
    PubMed     Abstract available


  86. THOMAS RP, Nagpal S, Iv M, Soltys SG, et al
    Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.
    Clin Cancer Res. 2019 Sep 19. pii: 1078-0432.CCR-19-1421.
    PubMed     Abstract available


  87. PAPACHRISTODOULOU A, Silginer M, Weller M, Schneider H, et al
    Therapeutic targeting of TGF-beta ligands in glioblastoma using novel antisense oligonucleotides reduces the growth of experimental gliomas.
    Clin Cancer Res. 2019 Sep 17. pii: 1078-0432.CCR-17-3024.
    PubMed     Abstract available


  88. JUTHANI R, Madajewski B, Yoo B, Zhang L, et al
    Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-19-1834.
    PubMed     Abstract available


  89. CHAUVIN C, Joalland N, Perroteau J, Jarry U, et al
    NKG2D controls natural reactivity of Vgamma9Vdelta2 T lymphocytes against mesenchymal glioblastoma cells.
    Clin Cancer Res. 2019 Sep 10. pii: 1078-0432.CCR-19-0375.
    PubMed     Abstract available


  90. JI J, Xu R, Ding K, Bao G, et al
    Long noncoding RNA SChLAP1 forms a growth promoting complex with HNRNPL in human glioblastoma through stabilization of ACTN4 and activation of NF-kappaB signaling.
    Clin Cancer Res. 2019 Sep 6. pii: 1078-0432.CCR-19-0747.
    PubMed     Abstract available


  91. WERBROUCK C, Evangelista CCS, Lobon-Iglesias MJ, Barret E, et al
    TP53 pathway alterations drive radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG).
    Clin Cancer Res. 2019 Sep 3. pii: 1078-0432.CCR-19-0126.
    PubMed     Abstract available


  92. LI J, Xue Y, Wenger A, Sun Y, et al
    Individual Assignment of Adult Diffuse Gliomas into the EM/PM Molecular Subtypes Using a TaqMan Low-Density Array.
    Clin Cancer Res. 2019 Sep 3. pii: 1078-0432.CCR-19-0299.
    PubMed     Abstract available


    August 2019
  93. JIANG H, Shin DH, Nguyen TT, Fueyo J, et al
    Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.
    Clin Cancer Res. 2019 Aug 27. pii: 1078-0432.CCR-19-0405.
    PubMed     Abstract available


  94. BODEKER KL, Allen BG, Smith MC, Monga V, et al
    First-in-human phase 1 clinical trial of pharmacological ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma.
    Clin Cancer Res. 2019 Aug 19. pii: 1078-0432.CCR-19-0594.
    PubMed     Abstract available


    July 2019
  95. WEN PY, Reardon DA, Armstrong TS, Phuphanich S, et al
    A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma.
    Clin Cancer Res. 2019 Jul 18. pii: 1078-0432.CCR-19-0261.
    PubMed     Abstract available


  96. JUAREZ-CHAMBI RM, Kut C, Rico-Jimenez JJ, Chaichana KL, et al
    AI-Assisted In Situ Detection of Human Glioma Infiltration Using a Novel Computational Method for Optical Coherence Tomography.
    Clin Cancer Res. 2019 Jul 17. pii: 1078-0432.CCR-19-0854.
    PubMed     Abstract available


  97. YANG ZJ, Du F, Yuelling LW, Lee EH, et al
    Leukotriene synthesis is critical for medulloblastoma progression.
    Clin Cancer Res. 2019 Jul 12. pii: 1078-0432.CCR-18-3549.
    PubMed     Abstract available


  98. TIEN AC, Li J, Bao X, DeRogatis A, et al
    A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.
    Clin Cancer Res. 2019 Jul 8. pii: 1078-0432.CCR-19-0133.
    PubMed     Abstract available


  99. JONSSON P, Lin AL, Young RJ, DiStefano NM, et al
    Genomic correlates of disease progression and treatment response in prospectively characterized gliomas.
    Clin Cancer Res. 2019 Jul 1. pii: 1078-0432.CCR-19-0032.
    PubMed     Abstract available


    June 2019
  100. RAPP C, Dettling S, Liu F, Ull AT, et al
    Cytotoxic T-cells and their activation status are independent prognostic markers in meningiomas.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-19-0389.
    PubMed     Abstract available


  101. KATAGI H, Louis N, Unruh D, Sasaki T, et al
    Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-18-3890.
    PubMed     Abstract available


  102. FECCI PE, Champion CD, Hoj J, McKernan C, et al
    The Evolving Modern Management of Brain Metastasis.
    Clin Cancer Res. 2019 Jun 18. pii: 1078-0432.CCR-18-1624.
    PubMed     Abstract available


    May 2019
  103. SMITH SJ, Tyler B, Gould TWA, Veal GJ, et al
    Overall survival in malignant glioma is significantly prolonged by neurosurgical delivery of etoposide and temozolomide from a thermo-responsive biodegradable paste.
    Clin Cancer Res. 2019 May 21. pii: 1078-0432.CCR-18-3850.
    PubMed     Abstract available


    April 2019
  104. COHEN JV, Sullivan RJ
    Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma.
    Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-18-0836.
    PubMed     Abstract available


  105. MORIKAWA A, de Stanchina E, Pentsova E, Kemeny MM, et al
    Phase I study of intermittent high dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases.
    Clin Cancer Res. 2019 Apr 15. pii: 1078-0432.CCR-18-3502.
    PubMed     Abstract available


    March 2019
  106. IDBAIH A, Canney M, Belin L, Desseaux C, et al
    Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma.
    Clin Cancer Res. 2019 Mar 19. pii: 1078-0432.CCR-18-3643.
    PubMed     Abstract available


  107. LI H, Li J, Chen L, Qi S, et al
    HERC3-mediated SMAD7 ubiquitination degradation promotes autophagy-induced EMT and chemoresistance in glioblastoma.
    Clin Cancer Res. 2019 Mar 12. pii: 1078-0432.CCR-18-3791.
    PubMed     Abstract available


  108. LAMANO JB, Lamano JB, Li YD, DiDomenico JD, et al
    Glioblastoma-Derived IL-6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
    Clin Cancer Res. 2019 Mar 1. pii: 1078-0432.CCR-18-2402.
    PubMed     Abstract available


    February 2019
  109. TOMASZEWSKI W, Sanchez-Perez L, Gajewski TF, Sampson JH, et al
    Brain Tumor Micro-environment and Host State - Implications for Immunotherapy.
    Clin Cancer Res. 2019 Feb 25. pii: 1078-0432.CCR-18-1627.
    PubMed     Abstract available


  110. LASSMAN AB, Roberts-Rapp LA, Sokolova I, Song M, et al
    Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-3034.
    PubMed     Abstract available


  111. HALL PE, Lewis R, Syed N, Shaffer R, et al
    A Phase I study of pegylated arginine deiminase (pegargiminase), cisplatin and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-3729.
    PubMed     Abstract available


  112. IPPEN FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, et al
    The dual PI3K/mTOR-pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-3049.
    PubMed     Abstract available


  113. ZHANG Q, Zhang Y, Chen Y, Qian J, et al
    A novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial-mesenchymal transition, metastases and improves cancer immunity in preclinical lung cancer models.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-2548.
    PubMed     Abstract available


  114. SIM HW, Nejad R, Zhang W, Nassiri F, et al
    Tissue 2-hydroxyglutarate as a biomarker for isocitrate dehydrogenase (IDH) mutations in gliomas.
    Clin Cancer Res. 2019 Feb 18. pii: 1078-0432.CCR-18-3205.
    PubMed     Abstract available


    January 2019
  115. INDIRA CHANDRAN V, Welinder C, Mansson AS, Offer S, et al
    Ultrasensitive immunoprofiling of plasma extracellular vesicles identifies syndecan-1 as a potential tool for minimally invasive diagnosis of glioma.
    Clin Cancer Res. 2019 Jan 24. pii: 1078-0432.CCR-18-2946.
    PubMed     Abstract available


  116. FINK MA, Paland H, Herzog S, Grube M, et al
    L-Carnitine Mediated Tumor Cell Protection and Poor Patient Survival Associated with OCTN2 Overexpression in Glioblastoma Multiforme.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2380.
    PubMed     Abstract available


  117. YUN J, Hong MH, Kim SY, Park CW, et al
    YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-small-cell lung cancer.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2906.
    PubMed     Abstract available


  118. PARK J, Kwon M, Kim KH, Kim TS, et al
    Immune Checkpoint Inhibitor-Induced Reinvigoration of Tumor-Infiltrating CD8(+) T Cells is Determined by Their Differentiation Status in Glioblastoma.
    Clin Cancer Res. 2019 Jan 18. pii: 1078-0432.CCR-18-2564.
    PubMed     Abstract available


  119. MAJZNER RG, Theruvath JL, Nellan A, Heitzeneder S, et al
    CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
    Clin Cancer Res. 2019 Jan 17. pii: 1078-0432.CCR-18-0432.
    PubMed     Abstract available


  120. BERGEN ES, Berghoff AS, Medjedovic M, Rudas M, et al
    Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases.
    Clin Cancer Res. 2019 Jan 15. pii: 1078-0432.CCR-18-1968.
    PubMed     Abstract available


  121. CHENG VWT, Soto MS, Khrapitchev AA, Perez-Balderas F, et al
    VCAM-1-targeted MRI Enables Detection of Brain Micrometastases from Different Primary Tumors.
    Clin Cancer Res. 2019;25:533-543.
    PubMed     Abstract available


  122. IORGULESCU JB, Torre M, Harary M, Smith TR, et al
    The Misclassification of Diffuse Gliomas: Rates and Outcomes.
    Clin Cancer Res. 2019 Jan 11. pii: 1078-0432.CCR-18-3101.
    PubMed     Abstract available


    December 2018
  123. HURVITZ SA, O'Shaughnessy J, Mason G, Yardley D, et al
    Central Nervous System Metastasis in Patients With HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival From SystHERs.
    Clin Cancer Res. 2018 Dec 28. pii: 1078-0432.CCR-18-2366.
    PubMed     Abstract available


  124. INDRACCOLO S, Lombardi G, Fassan M, Pasqualini L, et al
    Genetic, epigenetic and immunologic profiling of MMR-deficient relapsed glioblastoma.
    Clin Cancer Res. 2018 Dec 4. pii: 1078-0432.CCR-18-1892.
    PubMed     Abstract available


  125. HEGI ME, Genbrugge E, Gorlia T, Stupp R, et al
    MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide. A Pooled Analysis of Four Clinical Trials.
    Clin Cancer Res. 2018 Dec 4. pii: 1078-0432.CCR-18-3181.
    PubMed     Abstract available


    November 2018
  126. DAVIDSON TB, Lee AH, Hsu M, Sedighim S, et al
    Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation.
    Clin Cancer Res. 2018 Nov 29. pii: 1078-0432.CCR-18-1176.
    PubMed     Abstract available


  127. THULBORN KR, Lu A, Atkinson IC, Pauliah M, et al
    Residual Tumor Volume, Cell Volume Fraction and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR imaging.
    Clin Cancer Res. 2018 Nov 28. pii: 1078-0432.CCR-18-2079.
    PubMed     Abstract available


  128. ROBBINS DJ, Rodriguez-Blanco J, Li B, Shen C, et al
    A CK1alpha activator penetrates the brain, and shows efficacy against drug-resistant metastatic medulloblastoma.
    Clin Cancer Res. 2018 Nov 28. pii: 1078-0432.CCR-18-1319.
    PubMed     Abstract available


  129. CHOI BD, Maus MV, June CH, Sampson JH, et al
    ----Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
    Clin Cancer Res. 2018 Nov 16. pii: 1078-0432.CCR-18-1625.
    PubMed     Abstract available


  130. SPINO M, Kurz SC, Chiriboga L, Serrano J, et al
    Cell surface Notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase mutant glioma.
    Clin Cancer Res. 2018 Nov 5. pii: 1078-0432.CCR-18-2312.
    PubMed     Abstract available


    October 2018
  131. JIANG S, Eberhart CG, Lim M, Heo HY, et al
    Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy.
    Clin Cancer Res. 2018 Oct 26. pii: 1078-0432.CCR-18-1233.
    PubMed     Abstract available


  132. PANDITHARATNA E, Kilburn LB, Aboian MS, Kambhampati M, et al
    Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1345.
    PubMed     Abstract available


  133. AGNIHOTRI S, Mansouri S, Burrell K, Li M, et al
    Ketoconazole and Posaconazole Selectively Target HK2 Expressing Glioblastoma Cells.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1854.
    PubMed     Abstract available


  134. OSTI D, Del Bene M, Rappa G, Santos M, et al
    Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients.
    Clin Cancer Res. 2018 Oct 4. pii: 1078-0432.CCR-18-1941.
    PubMed     Abstract available


  135. PASSARO C, Alayo Q, DeLaura I, McNulty JJ, et al
    Arming an oncolytic herpes simplex virus Type 1 with a single chain fragment variable antibody against PD-1 for experimental glioblastoma therapy.
    Clin Cancer Res. 2018 Oct 2. pii: 1078-0432.CCR-18-2311.
    PubMed     Abstract available


  136. BERBERICH A, Kessler T, Thome CM, Pusch S, et al
    Targeting resistance against the MDM2 inhibitor RG7388 in glioblastoma cells by the MEK inhibitor trametinib.
    Clin Cancer Res. 2018 Oct 1. pii: 1078-0432.CCR-18-1580.
    PubMed     Abstract available


    September 2018
  137. UNRUH D, Mirkov S, Wray B, Drumm M, et al
    Methylation-dependent Tissue Factor suppression contributes to the reduced malignancy of IDH1 mutant gliomas.
    Clin Cancer Res. 2018 Sep 28. pii: 1078-0432.CCR-18-1222.
    PubMed     Abstract available


  138. CRUICKSHANKS N, Zhang Y, Hine S, Gibert M, et al
    Discovery and therapeutic exploitation of mechanisms of resistance to MET inhibitors in glioblastoma.
    Clin Cancer Res. 2018 Sep 10. pii: 1078-0432.CCR-18-0926.
    PubMed     Abstract available


  139. WAHL DR, Lawrence TS
    No sugar added: A new strategy to inhibit glioblastoma receptor tyrosine kinases.
    Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-2113.
    PubMed     Abstract available


    August 2018
  140. DAVARE MA, Henderson JJ, Agarwal A, Wagner JP, et al
    Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma.
    Clin Cancer Res. 2018 Aug 31. pii: 1078-0432.CCR-18-1052.
    PubMed     Abstract available


  141. BLAKELEY JO, Grossman SA, Chi AS, Mikkelsen T, et al
    Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.
    Clin Cancer Res. 2018 Aug 21. pii: 1078-0432.CCR-18-0110.
    PubMed     Abstract available


    July 2018
  142. MEEL MH, de Gooijer MC, Guillen Navarro M, Waranecki P, et al
    MELK inhibition in Diffuse Intrinsic Pontine Glioma.
    Clin Cancer Res. 2018 Jul 30. pii: 1078-0432.CCR-18-0924.
    PubMed     Abstract available


  143. ZINN PO, Singh SK, Kotrotsou A, Hassan I, et al
    A co-clinical radiogenomic validation study - Conserved magnetic resonance radiomic appearance of Periostin expressing Glioblastoma in patients and xenograft models.
    Clin Cancer Res. 2018 Jul 27. pii: 1078-0432.CCR-17-3420.
    PubMed     Abstract available


  144. ISHIDA CT, Zhang Y, Bianchetti E, Shu C, et al
    Metabolic Reprogramming by Dual AKT/ERK Inhibition Through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
    Clin Cancer Res. 2018 Jul 23. pii: 1078-0432.CCR-18-1040.
    PubMed     Abstract available


  145. ZHANG L, Sorensen M, Kristensen BW, Reifenberger G, et al
    The oncometabolite D-2-hydroxyglutarate is an intercellular mediator in IDH-mutant gliomas that inhibits both complement and T cells.
    Clin Cancer Res. 2018 Jul 13. pii: 1078-0432.CCR-17-3855.
    PubMed     Abstract available


  146. BARO M, Lopez Sambrooks C, Quijano A, Saltzman WM, et al
    Oligosaccharyltransferase inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity.
    Clin Cancer Res. 2018 Jul 2. pii: 1078-0432.CCR-18-0792.
    PubMed     Abstract available


    June 2018
  147. LEE EQ, Duda DG, Muzikansky A, Gerstner E, et al
    Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma.
    Clin Cancer Res. 2018 Jun 25. pii: 1078-0432.CCR-18-1025.
    PubMed     Abstract available


  148. JURATLI TA, Stasik S, Zolal A, Schuster C, et al
    TERT promoter mutation detection in cell-free tumor-derived DNA in patients with IDH wild-type glioblastomas - a pilot prospective study.
    Clin Cancer Res. 2018 Jun 25. pii: 1078-0432.CCR-17-3717.
    PubMed     Abstract available


  149. DANKNER M, Lajoie M, Moldoveanu D, Nguyen TT, et al
    Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma.
    Clin Cancer Res. 2018 Jun 14. pii: 1078-0432.CCR-17-3384.
    PubMed     Abstract available


  150. BUERKI RA, Chheda ZS, Okada H
    Immunotherapy of Primary Brain Tumors: Facts and Hopes.
    Clin Cancer Res. 2018 Jun 5. pii: 1078-0432.CCR-17-2769.
    PubMed     Abstract available


    May 2018
  151. NODA M, Okayama H, Tachibana K, Sakamoto W, et al
    Glycosyltransferase gene expression identifies a poor prognostic colorectal cancer subtype associated with mismatch repair deficiency and incomplete glycan synthesis.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-17-3533.
    PubMed     Abstract available


  152. VOGELBAUM MA
    Targeted Therapies for Brain Tumors: Will They Ever Deliver?
    Clin Cancer Res. 2018 May 24. pii: 1078-0432.CCR-18-0855.
    PubMed     Abstract available


  153. SANAI N, Li J, Boerner J, Stark K, et al
    Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.
    Clin Cancer Res. 2018 May 24. pii: 1078-0432.CCR-17-3348.
    PubMed     Abstract available


  154. LU CF, Hsu FT, Hsieh KL, Kao YJ, et al
    Machine Learning-Based Radiomics for Molecular Subtyping of Gliomas.
    Clin Cancer Res. 2018 May 22. pii: 1078-0432.CCR-17-3445.
    PubMed     Abstract available


  155. ZHANG Y, Ishida CT, Ishida W, Lo SL, et al
    Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and elicits Synthetic Lethality in Glioblastoma.
    Clin Cancer Res. 2018 May 15. pii: 1078-0432.CCR-18-0260.
    PubMed     Abstract available


    April 2018
  156. WILDES TJ, Grippin A, Dyson KA, Wummer BM, et al
    Cross-talk between T cells and hematopoietic stem cells during adoptive cellular therapy for malignant glioma.
    Clin Cancer Res. 2018 Apr 30. pii: 1078-0432.CCR-17-3061.
    PubMed     Abstract available


  157. GEDEON PC, Schaller TH, Chitneni SK, Choi BD, et al
    A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma.
    Clin Cancer Res. 2018 Apr 27. pii: 1078-0432.CCR-17-0126.
    PubMed     Abstract available


  158. KESARWANI P, Prabhu A, Kant S, Kumar P, et al
    Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0041.
    PubMed     Abstract available


  159. JACKSON CM, Lim M
    Immunotherapy for glioblastoma: playing chess, not checkers.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0491.
    PubMed     Abstract available


  160. MARTINEZ-RICARTE F, Mayor R, Martinez-Saez E, Rubio-Perez C, et al
    Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumour DNA from cerebrospinal fluid.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-17-3800.
    PubMed     Abstract available


    March 2018
  161. SAHA D, Wakimoto H, Peters CW, Antoszczyk SJ, et al
    Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1717.
    PubMed     Abstract available


  162. WORONIECKA KI, Rhodin KE, Chongsathidkiet P, Keith KA, et al
    T-Cell Dysfunction in Glioblastoma: Applying a New Framework.
    Clin Cancer Res. 2018 Mar 28. pii: 1078-0432.CCR-18-0047.
    PubMed     Abstract available


  163. DETTLING S, Stamova S, Warta R, Schnolzer M, et al
    Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-cell Targets in Human IDH-Mutant Glioma.
    Clin Cancer Res. 2018 Mar 21. pii: 1078-0432.CCR-17-1839.
    PubMed     Abstract available


  164. NAKASHIMA H, Nguyen T, Kasai K, Passaro C, et al
    Toxicity and efficacy of a novel GADD34-expressing oncolytic HSV-1 for the treatment of experimental glioblastoma.
    Clin Cancer Res. 2018 Mar 6. pii: 1078-0432.CCR-17-2954.
    PubMed     Abstract available


  165. LADOMERSKY E, Zhai L, Lenzen A, Lauing KL, et al
    IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-3573.
    PubMed     Abstract available


    February 2018
  166. NISHIYAMA A, Yamada T, Kita K, Wang R, et al
    Foretinib overcomes entrectinib resistance associated with the NTRK1 G667C mutation in NTRK1 fusion-positive tumor cells in a brain metastasis model.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-1623.
    PubMed     Abstract available


  167. LI XN, Kogiso M, Qi L, Braun FK, et al
    Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX models.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-2256.
    PubMed     Abstract available


  168. MOHME M, Schliffke S, Maire CL, Runger A, et al
    Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
    Clin Cancer Res. 2018 Feb 14. pii: 1078-0432.CCR-17-2617.
    PubMed     Abstract available


  169. HOLLON TC, Orringer DA
    Shedding light on IDH1 mutation in gliomas.
    Clin Cancer Res. 2018 Feb 13. pii: 1078-0432.CCR-18-0011.
    PubMed     Abstract available


  170. WORONIECKA K, Chongsathidkiet P, Rhodin KE, Kemeny HR, et al
    T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma.
    Clin Cancer Res. 2018 Feb 7. pii: 1078-0432.CCR-17-1846.
    PubMed     Abstract available


  171. GORDON RE, Zhang L, Peri S, Kuo YM, et al
    Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2923.
    PubMed     Abstract available


  172. KABRAJI S, Ni J, Lin N, Xie S, et al
    Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3351.
    PubMed     Abstract available


    January 2018
  173. GOMEZ S, Garrido-Garcia A, Garcia-Gerique L, Lemos I, et al
    A novel method for rapid molecular subgrouping of medulloblastoma.
    Clin Cancer Res. 2018 Jan 19. pii: 1078-0432.CCR-17-2243.
    PubMed     Abstract available


  174. NIMMERVOLL B, Boulos N, Bianski BM, Dapper J, et al
    Establishing A Preclinical Multidisciplinary Board for Brain Tumors.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2168.
    PubMed     Abstract available


    December 2017
  175. PAL J, Patil V, Kumar A, Kaur K, et al
    Loss-of-function mutations in Calcitonin receptor (CALCR) identify highly aggressive glioblastoma with poor outcome.
    Clin Cancer Res. 2017 Dec 20. pii: 1078-0432.CCR-17-1901.
    PubMed     Abstract available


  176. UCKERMANN O, Juratli TA, Galli R, Conde M, et al
    Optical analysis of glioma: Fourier-transform infrared spectroscopy reveals the IDH1 mutation status.
    Clin Cancer Res. 2017 Dec 19. pii: 1078-0432.CCR-17-1795.
    PubMed     Abstract available


  177. SU YT, Chen R, Wang H, Song H, et al
    Novel Targeting of Transcription and Metabolism in Glioblastoma.
    Clin Cancer Res. 2017 Dec 18. pii: 1078-0432.CCR-17-2032.
    PubMed     Abstract available


  178. JIN X, Jin X, Kim LJY, Dixit D, et al
    Inhibition of ID1-BMPR2 intrinsic signaling sensitizes glioma stem cells to differentiation therapy.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1529.
    PubMed     Abstract available


    November 2017
  179. CHANG K, Bai HX, Zhou H, Su C, et al
    Residual Convolutional Neural Network for Determination of IDH Status in Low- and High-grade Gliomas from MR Imaging.
    Clin Cancer Res. 2017 Nov 22. pii: clincanres.2236.2017.
    PubMed     Abstract available


  180. WEISS T, Schneider H, Silginer M, Steinle A, et al
    NKG2D-dependent anti-tumor effects of chemotherapy and radiotherapy against glioblastoma.
    Clin Cancer Res. 2017 Nov 21. pii: clincanres.1766.2017.
    PubMed     Abstract available


  181. MIGLIORINI D, Dietrich PY, Stupp R, Linette GP, et al
    CAR-T cell Therapies in Glioblastoma: a first look.
    Clin Cancer Res. 2017 Nov 20. pii: clincanres.2871.2017.
    PubMed     Abstract available


  182. NANDHU MS, Behera P, Bhaskaran V, Longo SL, et al
    Development of a function-blocking antibody against fibulin-3 as targeted reagent for glioblastoma.
    Clin Cancer Res. 2017 Nov 16. pii: clincanres.1628.2017.
    PubMed     Abstract available


  183. CHEN Q, Cai J, Wang Q, Wang Y, et al
    Long non-coding RNA NEAT1, regulated by the EGFR pathway, contributes to glioblastoma progression through the WNT/beta-Catenin pathway by scaffolding EZH2.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.0605.2017.
    PubMed     Abstract available


  184. WICK W, Kessler T
    Drug repositioning meets precision in glioblastoma.
    Clin Cancer Res. 2017 Nov 13. pii: clincanres.2989.2017.
    PubMed     Abstract available


    October 2017
  185. BYRON SA, Tran NL, Halperin RF, Phillips JJ, et al
    Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma.
    Clin Cancer Res. 2017 Oct 26. pii: clincanres.0963.2017.
    PubMed     Abstract available


  186. PRICEMAN SJ, Tilakawardane D, Jeang B, Murad JP, et al
    Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.2041.2017.
    PubMed     Abstract available


  187. FAN Y, Zhu X, Xu Y, Lu X, et al
    Cell-cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non-small cell lung cancer.
    Clin Cancer Res. 2017 Oct 13. pii: clincanres.1582.2017.
    PubMed     Abstract available


  188. ACERBI F, Broggi M, Schebesch KM, Hohne J, et al
    Fluorescein-guided surgery for resection of high-grade gliomas: A multicentric prospective phase II study (FLUOGLIO).
    Clin Cancer Res. 2017 Oct 10. pii: clincanres.1184.2017.
    PubMed     Abstract available


    September 2017
  189. AVRIL T, Etcheverry A, Pineau R, Obacz J, et al
    CD90 expression controls migration and predicts dasatinib response in glioblastoma.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.1549.2017.
    PubMed     Abstract available


  190. LI J, Wu J, Bao X, Honea N, et al
    Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients using an IVIVE-PBPK Modeling Approach.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.0983.2017.
    PubMed     Abstract available


  191. MULLER-GREVEN GM, Carlin C, Burgett ME, Ahluwalia MS, et al
    Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0249.2017.
    PubMed     Abstract available


  192. CHOI SH, Stuckey DW, Pignatta S, Reinshagen C, et al
    Tumor resection boosts therapeutic efficacy of encapsulated stem cells expressing a highly secretable variant of interferon-beta in glioblastomas.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0077.2017.
    PubMed     Abstract available


    August 2017
  193. FELSBERG J, Hentschel B, Kaulich K, Gramatzki D, et al
    Prognostic role of Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified primary and recurrent glioblastomas.
    Clin Cancer Res. 2017 Aug 29. pii: clincanres.0890.2017.
    PubMed     Abstract available


  194. ALEXANDER BM, Ba S, Berger MS, Berry DA, et al
    Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0764.2017.
    PubMed     Abstract available


  195. OLMEZ I, Brenneman B, Xiao A, Serbulea V, et al
    Combined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0803.2017.
    PubMed     Abstract available


  196. WANG G, Shen J, Sun J, Jiang Z, et al
    Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/beta-catenin Signaling.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0774.2017.
    PubMed     Abstract available


    July 2017
  197. ZHANG CB, Cheng W, Ren X, Wang Z, et al
    Tumor Purity As an Underlying Key Factor in Glioma.
    Clin Cancer Res. 2017 Jul 28. pii: clincanres.2598.2016.
    PubMed     Abstract available


  198. ZHAI L, Ladomersky E, Lauing KL, Wu M, et al
    Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0120.2017.
    PubMed     Abstract available


  199. PATEL SH, Poisson LM, Brat DJ, Zhou Y, et al
    T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower Grade Gliomas: A TCGA/TCIA Project.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0560.2017.
    PubMed     Abstract available


  200. OIZEL K, Chauvin C, Oliver L, Gratas C, et al
    Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity.
    Clin Cancer Res. 2017 Jul 18. pii: clincanres.3102.2016.
    PubMed     Abstract available


  201. FAN QW, Nicolaides TP, Weiss WA
    Inhibiting 4EBP1 in glioblastoma.
    Clin Cancer Res. 2017 Jul 10. pii: clincanres.0042.2017.
    PubMed     Abstract available


  202. CANELLA A, Welker AM, Yoo JY, Xu J, et al
    Efficacy of Onalespib a Long-acting Second Generation HSP90 Inhibitor as a Single Agent and in Combination with Temozolomide Against Malignant Gliomas.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.3151.2016.
    PubMed     Abstract available


    June 2017
  203. ELLINGSON BM, Gerstner E, Smits M, Huang RY, et al
    Diffusion MRI phenotypes predict overall survival benefitfrom anti-VEGF monotherapy in recurrent glioblastoma:Converging evidence from phase II trials.
    Clin Cancer Res. 2017 Jun 27. pii: clincanres.2844.2016.
    PubMed     Abstract available


  204. COOK SANGAR ML, Genovesi LA, Nakamoto MW, Davis MJ, et al
    Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models.
    Clin Cancer Res. 2017 Jun 21. pii: clincanres.2943.2016.
    PubMed     Abstract available


    May 2017
  205. GEOERGER B, Bourdeaut F, DuBois SG, Fischer M, et al
    A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
    Clin Cancer Res. 2017;23:2433-2441.
    PubMed     Abstract available


  206. SLANEY CY, von Scheidt B, Davenport AJ, Beavis PA, et al
    Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.
    Clin Cancer Res. 2017;23:2478-2490.
    PubMed     Abstract available


    April 2017
  207. BAKAS S, Akbari H, Pisapia J, Martinez-Lage M, et al
    In vivo detection of EGFRvIII in glioblastoma via perfusion magnetic resonance imaging signature consistent with deep peritumoral infiltration: the phi index.
    Clin Cancer Res. 2017 Apr 20. pii: clincanres.1871.2016.
    PubMed     Abstract available



  208. Correction: Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis.
    Clin Cancer Res. 2017;23:2127.
    PubMed    


  209. BATICH KA, Reap EA, Archer GE, Sanchez-Perez L, et al
    Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
    Clin Cancer Res. 2017;23:1898-1909.
    PubMed     Abstract available


  210. BI WL, Horowitz P, Greenwald NF, Abedalthagafi M, et al
    Landscape of Genomic Alterations in Pituitary Adenomas.
    Clin Cancer Res. 2017;23:1841-1851.
    PubMed     Abstract available


    March 2017
  211. LEE H, Shields AF, Siegel BA, Miller KD, et al
    64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 15. pii: clincanres.3193.2016.
    PubMed     Abstract available



  212. Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
    Clin Cancer Res. 2017;23:1361.
    PubMed    


    February 2017
  213. BLOCH O, Lim M, Sughrue ME, Komotar RJ, et al
    Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.1369.2016.
    PubMed     Abstract available


    January 2017
  214. RING EK, Markert JM, Gillespie GY, Friedman GK, et al
    Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.
    Clin Cancer Res. 2017;23:342-350.
    PubMed     Abstract available


    December 2016
  215. HOLDHOFF M, Guner G, Rodriguez FJ, Hicks JL, et al
    Absence of cytomegalovirus in glioblastoma and other high-grade gliomas by real-time PCR, immunohistochemistry and in situ hybridization.
    Clin Cancer Res. 2016 Dec 29. pii: clincanres.1490.2016.
    PubMed     Abstract available


  216. PORTNOW J, Synold TW, Badie B, Tirughana R, et al
    Neural stem cell-based anti-cancer gene therapy: a first-in-human study in recurrent high grade glioma patients.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.1518.2016.
    PubMed     Abstract available


    November 2016
  217. WANG Z, Hao Y, Zhang CB, Wang Z, et al
    The landscape of viral expression reveals clinically relevant viruses with potential capability of promoting malignancy in lower grade glioma.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.1495.2016.
    PubMed     Abstract available


  218. DADEY DY, Kapoor V, Hoye K, Khudanyan A, et al
    Antibody targeting GRP78 enhances the efficacy of radiation therapy in human glioblastoma and non-small-cell lung cancer cell lines and tumor models.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1935.2016.
    PubMed     Abstract available


    October 2016
  219. ELLIOTT JT, Marra K, Evans LT, Davis SC, et al
    Simultaneous in vivo fluorescent markers for perfusion, protoporphyrin metabolism and EGFR expression for optically guided identification of orthotopic glioma.
    Clin Cancer Res. 2016 Oct 31. pii: clincanres.1400.2016.
    PubMed     Abstract available


  220. KICKINGEREDER P, Gotz M, Muschelli J, Wick A, et al
    Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
    Clin Cancer Res. 2016.
    PubMed     Abstract available


  221. STEEG PS, Zimmer AS, Gril B
    Therapeutics for Brain Metastases, Version 3.
    Clin Cancer Res. 2016 Oct 10. pii: clincanres.2035.2016.
    PubMed     Abstract available


    September 2016
  222. RAMACHANDRAN M, Yu D, Dyczynski M, Baskaran S, et al
    Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus.
    Clin Cancer Res. 2016 Sep 16. pii: clincanres.0925.2016.
    PubMed     Abstract available


  223. POINTER KB, Clark PA, Eliceiri KW, Salamat MS, et al
    Non-torsadogenic human Ether-a-go-go Related Gene (hERG) inhibitors are associated with better survival for high hERG-expressing glioblastoma patients.
    Clin Cancer Res. 2016 Sep 15. pii: clincanres.3169.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: